Drugs that contain Tipiracil Hydrochloride; Trifluridine
1. Drug name - LONSURF
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9527833 | TAIHO ONCOLOGY | Stable crystal form of tipiracil hydrochloride and crystallization method for the same |
Jun, 2034
(11 years from now) | |
| US10457666 | TAIHO ONCOLOGY | Stable crystal form of tipiracil hydrochloride and crystallization method for the same |
Jun, 2034
(11 years from now) | |
| EP3012255A4 | TAIHO ONCOLOGY | Stabilized Crystal Of Tipiracil Hydrochloride, And Crystallization Method For Same |
Jun, 2034
(11 years from now) | |
| EP3012255B1 | TAIHO ONCOLOGY | Stable Crystal Form Of Tipiracil Hydrochloride And Crystallization Method For The Same |
Jun, 2034
(11 years from now) | |
| EP3012255A1 | TAIHO ONCOLOGY | Stable Crystal Form Of Tipiracil Hydrochloride And Crystallization Method For The Same |
Jun, 2034
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE46284 | TAIHO ONCOLOGY | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
Sep, 2029
(6 years from now) | |
| US10456399 | TAIHO ONCOLOGY | Method for treating cancer patients with severe renal impairment |
Feb, 2037
(14 years from now) | |
| US10960004 | TAIHO ONCOLOGY | Method for treating cancer patients with severe renal impairment |
Feb, 2037
(14 years from now) | |
Treatment: Treatment of adults with metastatic gastric or gja previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropiate, her2/neu-targeted therapy; treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy; Method of treating cancer by detecting a creatinine clearance of a patient and administering lonsurf
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 6.14MG BASE;15MG | TABLET;ORAL | Prescription |
| EQ 8.19MG BASE;20MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.